IDEXX Laboratories Announces Board Changes
Ticker: IDXX · Form: 8-K · Filed: Feb 14, 2025 · CIK: 874716
| Field | Detail |
|---|---|
| Company | Idexx Laboratories Inc /De (IDXX) |
| Form Type | 8-K |
| Filed Date | Feb 14, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.10 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-change, governance
Related Tickers: IDXX
TL;DR
IDEXX board shakeup: Sweeney out, Dr. St. John in.
AI Summary
On February 13, 2025, IDEXX Laboratories, Inc. reported a change in its board of directors. Specifically, the company announced the departure of director Michael J. Sweeney and the election of new director Dr. Sarah E. K. St. John. These changes are effective immediately.
Why It Matters
Changes in a company's board of directors can signal shifts in strategic direction or governance, which may impact investor confidence and future performance.
Risk Assessment
Risk Level: low — The filing reports routine changes in board composition, which typically carry low immediate risk.
Key Players & Entities
- IDEXX LABORATORIES INC /DE (company) — Registrant
- Michael J. Sweeney (person) — Departing Director
- Dr. Sarah E. K. St. John (person) — Newly Elected Director
- February 13, 2025 (date) — Date of earliest event reported
FAQ
Who is the departing director from IDEXX Laboratories?
Michael J. Sweeney is the departing director.
Who is the newly elected director at IDEXX Laboratories?
Dr. Sarah E. K. St. John has been elected as a new director.
What is the effective date of these board changes?
The changes are effective as of February 13, 2025.
What is the principal executive office address for IDEXX Laboratories?
The principal executive offices are located at One IDEXX Drive, Westbrook, Maine 04092.
Under which section of the Securities Exchange Act is this report filed?
This Current Report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 486 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2025-02-14 16:00:15
Key Financial Figures
- $0.10 — ange on which registered Common Stock, $0.10 par value per share IDXX NASDAQ Global
Filing Documents
- idxx-20250213.htm (8-K) — 26KB
- idxx-20250213_g1.jpg (GRAPHIC) — 47KB
- 0000874716-25-000011.txt ( ) — 283KB
- idxx-20250213.xsd (EX-101.SCH) — 2KB
- idxx-20250213_def.xml (EX-101.DEF) — 15KB
- idxx-20250213_lab.xml (EX-101.LAB) — 26KB
- idxx-20250213_pre.xml (EX-101.PRE) — 15KB
- idxx-20250213_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IDEXX LABORATORIES, INC. Date: February 14, 2025 By: /s/ Sharon E. Underberg Sharon E. Underberg Executive Vice President, General Counsel and Corporate Secretary 2